Understanding how hereditary kidney cancers develop and progress
Deciphering Clonal Evolution in Hereditary Renal Cell Carcinomas
This study is looking at how hereditary kidney cancers grow and change in people with Von Hippel-Lindau (VHL) disease, and it invites patients to help by sharing their tumor samples so researchers can find better ways to treat kidney cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Francis Crick Institute, LTD NIH-funded |
| Lab location | 1 site (London, United Kingdom) |
| Project ID | NIH-10916249 on NIH RePORTER |
What this research studies
This research investigates the factors that drive the growth and progression of hereditary kidney cancers, specifically in patients with Von Hippel-Lindau (VHL) disease. By profiling multiple tumors from these patients, the study aims to uncover the molecular landscape, tumor microenvironment, and metabolic factors that influence cancer evolution. Patients will be recruited to participate in a cohort study where their tumors will be monitored and analyzed using advanced imaging and genetic sequencing techniques. The goal is to gain insights that could lead to improved treatment strategies for kidney cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Von Hippel-Lindau disease who are at risk of developing clear cell renal cell carcinoma.
Not a fit: Patients without a diagnosis of Von Hippel-Lindau disease or those with sporadic kidney cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and treatment options for patients with hereditary kidney cancers.
How similar studies have performed: Previous research has shown success in understanding cancer evolution through genetic profiling, making this approach promising but still innovative in the context of hereditary kidney cancers.
Where this research is happening
London, United Kingdom
- Francis Crick Institute, LTD — London, United Kingdom (Active)
Researchers
- Principal investigator: Turajlic, Samra — Francis Crick Institute, LTD
- Study coordinator: Turajlic, Samra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.